Severe Rsv Disease
Pediatric RSV Prevention: Critical Insights on Immunoprophylaxis
This activity is supported by an educational grant from Sanofi US.
RSV triples a person’s risk for death within 1 year, study shows
VIENNA — After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus across the finish line in 2023.
Study: Three-quarters of infants protected against RSV last season
Nearly 80% of infants born in a California health system were exposed to nirsevimab or the maternal respiratory syncytial virus vaccine in 2023-2024, the first season in which they were available, according to study findings.
Pediatric RSV Prevention: Advances in Disease State, Immunization, and Interprofessional Care
This activity is supported by an educational grant from Sanofi US.
Updates in Preventing Pediatric RSV: Rapid Response From IDWeek
This activity is supported by an educational grant from Sanofi US.
Preventing Pediatric RSV: Latest Strategies in Immunoprophylaxis
This activity is supported by an educational grant from Sanofi US.
Pediatric RSV Prevention – Unlocking New Insights
This activity is supported by an educational grant from Sanofi US.
COVID-19 disrupted RSV seasons, leading to more hospitalizations
COVID-19 mitigation measures disrupted the circulation of respiratory syncytial virus, leading to atypical season in 2021 and 2022 that saw higher rates of hospitalization among young children, according to research published in Pediatrics.
Underrepresented populations, those with lower income at higher risk for severe RSV
Older adults from underrepresented populations and those with lower incomes were more likely to have risk factors for severe respiratory syncytial virus disease, a study showed.
Nirsevimab highly effective at preventing RSV hospitalization in infants, report shows
The monoclonal antibody nirsevimab is 90% effective at preventing respiratory syncytial virus hospitalization in infants, according to research published in MMWR.